Analytical Data
-
基因名
SPG3A
- Application
-
别名
ATL1; GBP3; SPG3A; Atlastin-1; Brain-specific GTP-binding protein; GTP-binding protein 3; GBP-3; hGBP3; Guanine nucleotide-binding protein 3; Spastic paraplegia 3 protein A
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8WXF7
-
表达区间
1-558aa
-
氨基酸序列
MAKNRRDRNSWGGFSEKTYEWSSEEEEPVKKAGPVQVLIVKDDHSFELDETALNRILLSE AVRDKEVVAVSVAGAFRKGKSFLMDFMLRYMYNQESVDWVGDYNEPLTGFSWRGGSERET TGIQIWSEIFLINKPDGKKVAVLLMDTQGTFDSQSTLRDSATVFALSTMISSIQVYNLSQ NVQEDDLQHLQLFTEYGRLAMEETFLKPFQSLIFLVRDWSFPYEFSYGADGGAKFLEKRL KVSGNQHEELQNVRKHIHSCFTNISCFLLPHPGLKVATNPNFDGKLKEIDDEFIKNLKIL IPWLLSPESLDIKEINGNKITCRGLVEYFKAYIKIYQGEELPHPKSMLQATAEANNLAAV ATAKDTYNKKMEEICGGDKPFLAPNDLQTKHLQLKEESVKLFRGVKKMGGEEFSRRYLQQ LESEIDELYIQYIKHNDSKNIFHAARTPATLFVVIFITYVIAGVTGFIGLDIIASLCNMI MGLTLITLCTWAYIRYSGEYRELGAVIDQVAAALWDQGSTNEALYKLYSAAATHRHLYHQ AFPTPKSESTEQSEKKKM
-
分子量
63.5 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SPG3A, or Spastic Paraplegia 3A, is a hereditary condition characterized by progressive weakness and spasticity in the lower limbs, often leading to significant mobility challenges. It is primarily caused by mutations in the ATL1 gene, which encodes for a protein involved in the myelination of axons in the nervous system. This disorder falls under a broader category of hereditary spastic paraplegias (HSPs), which are genetically and phenotypically diverse. The investigation of SPG3A recombinant proteins has gained interest in recent years due to their potential roles in elucidating the pathophysiological mechanisms underlying the disease. Studying these proteins can contribute to understanding the function of ATL1 in intracellular processes and its impact on neuronal health and function. By generating recombinant SPG3A proteins, researchers aim to explore the biochemical properties, stability, and interaction dynamics of the protein, which may provide insights into how mutations disrupt its normal function. Moreover, this research could pave the way for developing targeted therapeutic strategies to ameliorate symptoms and mitigate the disease's progression. Thus, the study of SPG3A recombinant proteins not only enhances our grasp of the molecular basis of spastic paraplegia but also offers potential avenues for future intervention and treatment options.
